Recent advances in targeted strategies for triple-negative breast cancer

Journal of Hematology & Oncology, Год журнала: 2023, Номер 16(1)

Опубликована: Авг. 28, 2023

Triple-negative breast cancer (TNBC), a highly aggressive subtype of cancer, negatively expresses estrogen receptor, progesterone and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is main form treatment for patients with TNBC, effectiveness TNBC still limited. The search more effective therapies urgent. Multiple targeted therapeutic strategies have emerged according to specific molecules signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, Notch poly ADP-ribose polymerase antibody-drug conjugates. Moreover, immune checkpoint example, pembrolizumab, atezolizumab, durvalumab, are widely explored clinic. We summarize recent advances therapy immunotherapy aim serving as reference development individualized future.

Язык: Английский

---

Adhesion, metastasis, and inhibition of cancer cells: a comprehensive review

Molecular Biology Reports, Год журнала: 2024, Номер 51(1)

Опубликована: Янв. 22, 2024

Abstract This comprehensive review delves into cancer’s complexity, focusing on adhesion, metastasis, and inhibition. It explores the pivotal role of these factors in disease progression therapeutic strategies. covers cancer cell migration, invasion, colonization distant organs, emphasizing significance adhesion intricate metastasis process. Inhibition approaches targeting molecules, such as integrins cadherins, are discussed. Overall, this contributes significantly to advancing research developing targeted therapies, holding promise for improving patient outcomes worldwide. Exploring different inhibition strategies revealed promising targets alleviate cells. The effectiveness integrin-blocking antibodies, small molecule inhibitors Focal kinase (FAK) Transforming Growth Factor β (TGF-β) pathway, combination therapies underscores their potential disrupt focal adhesions control epithelial-mesenchymal transition processes. identification FAK, Src, β-catenin SMAD4 offers valuable starting points further development therapies. complex interrelationships between metastatic signaling networks will be relevant new treatment approaches.

Язык: Английский

---

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Янв. 3, 2024

Abstract Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway has emerged as crucial contributor development, advancement, resistance This review article explores implications of PI3K in predictive, preventive, personalized medicine for BC. It emphasizes identification predictive biomarkers, such PIK3CA mutations, utility profiling guiding treatment decisions. The also discusses potential targeting preventive strategies customization therapy based on tumor stage, subtypes, genetic alterations. Overcoming inhibitors exploring combination therapies are addressed important considerations. While this field holds promise improving patient outcomes, further research clinical trials needed validate these approaches translate them into practice. Graphical

Язык: Английский

---

Simultaneous blockade of the CD73/EGFR axis inhibits tumor growth

IUBMB Life, Год журнала: 2025, Номер 77(1)

Опубликована: Янв. 1, 2025

Targeting the influencing factors in tumor growth and expansion microenvironment is one of key approaches to cancer immunotherapy. Various can cooperation stimulate growth, suppress anti-tumor immune responses, promote drug resistance, ultimately enhance recurrence. Therefore, due dependence close these axes, their combined targeting have a greater effect compared individual targeting. Among important affecting region, CD73 EGFR play an role by stimulating each other's expression function. we intended use nanocarriers that had previously produced characterized deliver anti-CD73 siRNAs murine breast 4T1 cells. Silencing could significantly induce cell death Downregulation CD73/EGFR axis also suppressed migratory proliferative potential This therapeutic strategy inhibited ovo model. These findings imply simultaneous be considered novel immunotherapeutic approach needs further investigation future studies.

Язык: Английский

---

Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies

Experimental Hematology and Oncology, Год журнала: 2024, Номер 13(1)

Опубликована: Авг. 6, 2024

Abstract The tumor microenvironment demonstrates great immunophenotypic heterogeneity, which has been leveraged in traditional immune-hot/cold categorization based on the abundance of intra-tumoral immune cells. By incorporating spatial contexture, immunophenotype was further elaborated into immune-inflamed, immune-excluded, and immune-desert. However, mechanisms underlying these different phenotypes are yet to be comprehensively elucidated. In this review, we discuss how cells interact collectively shape landscape from perspectives cells, extracellular matrix, cancer metabolism, summarize potential therapeutic options according distinct immunophenotypes for personalized precision medicine.

Язык: Английский

---

Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance

Non-coding RNA Research, Год журнала: 2024, Номер 9(2), С. 388 - 406

Опубликована: Фев. 1, 2024

Long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that do not code for proteins but have been linked to cancer development and metastasis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) influences crucial hallmarks through intricate molecular mechanisms, including proliferation, invasion, angiogenesis, apoptosis, the epithelial-mesenchymal transition (EMT). The current article highlights involvement of MALAT-1 in drug resistance, making it a potential target overcome chemotherapy refractoriness. It discusses impact on immunomodulatory molecules, such as major histocompatibility complex (MHC) PD-L1, leading immune evasion hindering anti-tumor responses. also plays significant role immunology by regulating diverse cell populations. In summary, is versatile regulator, influencing tumorigenesis, chemoresistance, immunotherapy Understanding its precise mechanisms developing targeted therapies, therapeutic strategies targeting show promise improving treatment outcomes. However, further research needed fully uncover biology translate these findings into clinical applications.

Язык: Английский

---

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 76, С. 12 - 21

Опубликована: Фев. 28, 2024

Язык: Английский

---

Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications

Experimental Hematology and Oncology, Год журнала: 2025, Номер 14(1)

Опубликована: Янв. 11, 2025

Abstract Immune checkpoint therapies have spearheaded drug innovation over the last decade, propelling cancer treatments toward a new era of precision therapies. Nonetheless, challenges low response rates and prevalent resistance underscore imperative for deeper understanding tumor microenvironment (TME) pursuit novel targets. Recent findings revealed profound impacts biomechanical forces within on immune surveillance progression in both murine models clinical settings. Furthermore, pharmacological or genetic manipulation mechanical checkpoints, such as PIEZO1, DDR1, YAP/TAZ, TRPV4, has shown remarkable potential activation eradication tumors. In this review, we delved into underlying mechanisms resulting intricate biological meaning TME, focusing mainly extracellular matrix, stiffness cells, synapses. We also summarized methodologies employed research translation derived from current evidence. This comprehensive review biomechanics will enhance functional role provide basic knowledge discovery therapeutic

Язык: Английский

---

Circulating Cell-Free DNA Integrity for Breast and Prostate Cancer: What Is the Landscape for Clinical Management of the Most Common Cancers in Women and Men?

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 900 - 900

Опубликована: Янв. 22, 2025

Breast cancer (BC) and prostate (PCa) are major health problems for women men worldwide. Although therapeutic approaches have increased, the complexity associated with their heterogeneity progression requires better ways to monitor them over time. Cell-free DNA integrity (cfDI) represents a viable alternative needle biopsy has potential be representative of at all stages. In addition advantages liquid in terms cost reduced invasiveness, cfDI can used detect repetitive elements (e.g., ALU LINE1), which could circumvent problem mutational BC PCa. this review, we summarise latest findings on studies The results show that improve early detection, metastasis, recurrence BC, while limited prevent its clinical value PCa from being fully defined. However, it is expected further near future will help introduce use as another biomarker monitoring patients.

Язык: Английский

---

Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

JAMA Network Open, Год журнала: 2025, Номер 8(2), С. e2461899 - e2461899

Опубликована: Фев. 26, 2025

Importance Black patients with metastatic breast cancer (mBC) have higher mortality rates than White despite advances in treatment. Objectives To examine whether different genomic profiles compared and there are inequities targeted treatment use between these groups. Design, Setting, Participants This retrospective, population-based cohort study assessed adult mBC who underwent profiling at academic institutions the US January 1, 2015, December 31, 2023. Data analysis was performed July 2023 2024. A validation also included. Exposures Targeted use. Main Outcomes Measures The main outcomes were differences circulating tumor DNA of phosphoinositide 3-kinase (PI3K), mammalian target rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors cancer. Results sample included 1327 women (mean [SD] age, 58.0 [12.8] years; 140 1057 White). had a significantly rate GATA3 single-nucleotide variants (odds ratio, 2.31; 95% CI, 1.17-4.54; P = .02) CCND2 copy number 4.63; 1.79-11.97; .002) on multivariate analysis. These validated evidence 27 224 patients. PIK3CA less likely to receive PI3K (1 17 [5.9%] vs 45 156 [28.8%]; .04), whereas no difference CDK4/6 mTOR inhibitors, which do not require targetable alteration. shorter overall survival from time testing Conclusions Relevance found somatic differences, survival, disparities inhibitor equal incidence alterations. Researchers should consider when designing future research interventions address striking persistent gap mBC.

Язык: Английский

---